GlassScriptPhysician profile
Colleen D Browne
NPI 1780777482
$8,619.03
in general payments reported to CMS, 2019-2025
48 companies · $2,104 in 2025
The $2,104 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,236 · 2022: $1,527 · 2023: $1,578 · 2024: $2,174 · 2025: $2,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,756 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,756.31 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,179.93 | 2021-2025 | |
| Lilly USA, LLC | $917.42 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $827.87 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $592.70 | 2021-2025 | Jardiance |
| Pfizer INC. | $568.75 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $349.62 | 2021-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $339.54 | 2022-2024 | Quviviq |
| Amgen INC. | $314.74 | 2021-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $278.08 | 2021-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $259.88 | 2021-2025 | Farxiga, Airsupra |
| Genzyme Corporation | $243.90 | 2023-2025 | |
| Exact Sciences Corporation | $219.49 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $202.86 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $196.66 | 2021-2024 | Xarelto |
| Ardelyx, INC. | $188.26 | 2024-2025 | Ibsrela |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Browne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.